BR9610386A - Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica - Google Patents

Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica

Info

Publication number
BR9610386A
BR9610386A BR9610386-8A BR9610386A BR9610386A BR 9610386 A BR9610386 A BR 9610386A BR 9610386 A BR9610386 A BR 9610386A BR 9610386 A BR9610386 A BR 9610386A
Authority
BR
Brazil
Prior art keywords
mdm2 protein
antagonizing
compound capable
oncogenic activity
partially
Prior art date
Application number
BR9610386-8A
Other languages
English (en)
Inventor
Bruno Tocque
Marie-Christin Dubs-Poterszman
Bohdan Wasylyk
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of BR9610386A publication Critical patent/BR9610386A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UTILIZAçãO DE UM COMPOSTO CAPAZ DE ANTAGONIZAR, AO MENOS PARCIALMENTE, A ATIVIDADE ONCOGêNICA DA PROTEìNA MDM2, UTILIZAçãO DE UM SCFV, DIRIGIDO CONTRA O DOMìNIO 1-134 DA PROTEìNA Mdm2, UTILIZAçãO DE UM áCIDO NUCLéICO CODIFICANDO PARA UM COMPOSTO CAPAZ DE ANTAGONIZAR A ATIVIDADE ONCOGêNICA DA PROTEìNA MDM2, VETOR VIRAL E COMPOSIçãO FARMACêUTICA. A presente invenção concerne à utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína Mdm2, para a preparação de uma composição farmacêutica destinada, mais particularmente, ao tratamento de cânceres em contexto p53 nulo. Ela se refere, ademais, a um vetor viral compreendendo uma seq³ência de ácido nucléico codificando para um composto capaz de inibir, ao menos parcialmente, a atividade oncogênica da proteína Mdm2, e a uma composição farmacêutica correspondente.
BR9610386-8A 1995-09-04 1996-09-02 Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica BR9610386A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9510331A FR2738151B1 (fr) 1995-09-04 1995-09-04 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
PCT/FR1996/001340 WO1997009343A2 (fr) 1995-09-04 1996-09-02 Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers

Publications (1)

Publication Number Publication Date
BR9610386A true BR9610386A (pt) 1999-10-13

Family

ID=9482234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610386-8A BR9610386A (pt) 1995-09-04 1996-09-02 Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica

Country Status (20)

Country Link
US (4) US20030060432A1 (pt)
EP (1) EP0848720B1 (pt)
JP (2) JPH11511980A (pt)
KR (1) KR100592916B1 (pt)
AT (1) ATE257711T1 (pt)
AU (1) AU722782B2 (pt)
BR (1) BR9610386A (pt)
CA (1) CA2228667C (pt)
CZ (1) CZ298806B6 (pt)
DE (1) DE69631335T2 (pt)
DK (1) DK0848720T3 (pt)
ES (1) ES2210386T3 (pt)
FR (1) FR2738151B1 (pt)
HU (1) HU223597B1 (pt)
IL (1) IL123514A (pt)
NO (1) NO319160B1 (pt)
PT (1) PT848720E (pt)
SK (1) SK287127B6 (pt)
WO (1) WO1997009343A2 (pt)
ZA (1) ZA967451B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620028D0 (en) 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
US6013786A (en) * 1997-08-22 2000-01-11 Hybridon, Inc. MDM2-specific antisense oligonucleotides
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
DE10109813A1 (de) * 2001-03-01 2002-09-12 Thomas Stanislawski Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen
EP2118123B1 (en) * 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
US20090018078A1 (en) * 2007-07-09 2009-01-15 Vinod Labhasetwar Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same
US20130149314A1 (en) 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
CA2947270A1 (en) * 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2020159504A1 (en) * 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
AU2018306436A1 (en) 2017-07-27 2020-02-13 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof

Also Published As

Publication number Publication date
FR2738151A1 (fr) 1997-03-07
NO980905L (no) 1998-03-02
MX9801407A (es) 1998-05-31
KR100592916B1 (ko) 2006-11-07
FR2738151B1 (fr) 1997-09-26
KR19990044356A (ko) 1999-06-25
PT848720E (pt) 2004-05-31
HU223597B1 (hu) 2004-10-28
HUP9900406A2 (hu) 1999-05-28
ZA967451B (en) 1997-03-10
US20140030319A1 (en) 2014-01-30
US20040209834A1 (en) 2004-10-21
SK28098A3 (en) 1998-08-05
SK287127B6 (sk) 2009-12-07
ES2210386T3 (es) 2004-07-01
HUP9900406A3 (en) 2002-04-29
AU6933496A (en) 1997-03-27
WO1997009343A3 (fr) 1997-05-29
JPH11511980A (ja) 1999-10-19
DE69631335T2 (de) 2004-12-02
IL123514A (en) 2006-10-31
CZ63098A3 (cs) 1998-06-17
ATE257711T1 (de) 2004-01-15
NO319160B1 (no) 2005-06-27
US20030060432A1 (en) 2003-03-27
NO980905D0 (no) 1998-03-02
WO1997009343A2 (fr) 1997-03-13
EP0848720B1 (fr) 2004-01-14
CA2228667A1 (fr) 1997-03-13
DK0848720T3 (da) 2004-04-19
IL123514A0 (en) 1998-10-30
US20080311608A1 (en) 2008-12-18
CA2228667C (fr) 2013-06-04
CZ298806B6 (cs) 2008-02-06
JP2011225571A (ja) 2011-11-10
AU722782B2 (en) 2000-08-10
EP0848720A2 (fr) 1998-06-24
DE69631335D1 (de) 2004-02-19

Similar Documents

Publication Publication Date Title
BR9610386A (pt) Utilização de um composto capaz de antagonizar, ao menos parcialmente, a atividade oncogênica da proteína mdm2, utilização de um scfv, dirigido contra o domínio 1-134 da proteína mdm2, utilização de um ácido nucléico codificado para um composto capaz de antagonizar a atividade oncogênica da proteína mdm2, vetor viral e composição farmacêutica
WO2000034265A3 (en) Quinoline-indole antimicrobial agents
WO2002002190A3 (en) Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
WO1998051294A3 (en) Method and composition for treating cancers
EP0943331A3 (en) Formulations containing oxaliplatin
MY120984A (en) Activated protein c formulations
AU2773599A (en) Medical, radiotherapy source vial
CA2350538A1 (en) Pyrazolopyrimidinone derivatives for the treatment of impotence
DK0973735T3 (da) Polyaromatiske antivirale præparater
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
FR2705673B1 (fr) Compositions comportant des dérivés d'acides aminés, leurs procédés de préparation et leurs utilisations.
AU4170197A (en) Pharmaceutical compounds
AU4363199A (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
HUP0400865A2 (hu) Hatóanyag-kombinációt tartalmazó készítmények szenvedély- vagy kábítószer-betegségek kezelésére és eljárás a készítmények előállítására
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
WO1999067238A3 (en) Tetrahydroquinoline-indole derivatives antimicrobial agents, their uses and compositions containing them
RU94040150A (ru) Стабильная лиофилизированная композиция тиотепа, способ ее получения
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
AU3260093A (en) Use of creatine phosphate or phosphoenolpyruvic acid for the treatment of tumours
WO2000021506A3 (en) Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy
AU1469097A (en) Pharmaceutical compounds
EP1073436A4 (en) IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI
WO1997035568A3 (en) Diclofenac/gamma-cyclodextrin inclusion compounds

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B15V Prolongation of time limit allowed
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: ALTERADO DE: RHONE-POULENC RORER S.A.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time